Obesity study: Berobenatide
Official title A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
ClinicalTrials.gov ID: NCT07792954
What this study is testing
What is Berobenatide?
Berobenatide is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for obesity.
Also referred to as PF-08653944.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults ≥18 years of age.
- BMI ≥28 kg/m²; or BMI ≥24 kg/m² and \<28 kg/m² with at least one weight-related comorbidity.
- Participants with T2D must have HbA1c 6.5% to 10.0%.
- At least one prior unsuccessful dietary weight-loss attempt.
You likely can't join if
- Significant recent weight change (\>5% within 3 months).
- Type 1 diabetes mellitus.
- History of pancreatitis.
- Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple endocrine neoplasia type 2 (MEN2).
- Recent bariatric surgery or obesity procedures.
- Pregnancy or breastfeeding.
The study team makes the final eligibility decision.
Where it is enrolling
- Hefei, Anhui, China
- Beijing, Beijing Municipality, China
- Chongqing, Chongqing Municipality, China
- Huizhou, Guangdong, China
- Hengshui, Hebei, China
- Harbin, Heilongjiang, China
- Luoyang, Henan, China
- Zhengzhou, Henan, China
- Wuhan, Hubei, China
- Changzhou, Jiangsu, China
- Nanjing, Jiangsu, China
- Nantong, Jiangsu, China
- Zhenjiang, Jiangsu, China
- Nanchang, Jiangxi, China
- Pingxiang, Jiangxi, China
- Changchun, Jilin, China
- Xi'an, Shaanxi, China
- Jinan, Shandong, China
- Shanghai, Shanghai Municipality, China
- Huzhou, Zhejiang, China
+ 2 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Hefei, Anhui, China; Beijing, Beijing Municipality, China; Chongqing, Chongqing Municipality, China; Huizhou, Guangdong, China; Hengshui, Hebei, China; Harbin, Heilongjiang, China and 16 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.